NETMANAGE INCORPORATED (NASD: NETM)
"Up 67.23% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/NETM.php

NetManage, Inc. and its subsidiaries develop and market software and service solutions that enable customers to access their corporate business applications, processes, and data. Its products include RUMBA, a connectivity software that connects personal computers (PCs) to IBM mainframe, iSeries systems, and UNIX host systems; ViewNow X Server and ViewNow InterDrive NFS connectivity software, which enables PCs to share files, and access and run X Windows applications with UNIX host systems; and OnWeb Web-to-Host, a browser-based product for deploying host access solutions. The company also provides OnWeb Server, a server-based solution that allows customers to leverage existing enterprise applications, information, and business processes, as well as to enable application publishing on the Web by mapping one or more human-based transactions to a Web-based presentation; and to generate .NET Assemblies, BizTalk adapters, JavaBean, EJB, and portlets from back-end transactions. In addition, it offers SOA Planner, a server product that non-invasively listens to host system interactions in real-time to capture common usage patterns; OnWeb for CICS, a software solution that transforms existing customer information control system data into standard XML for integration with other enterprise information systems or SOA initiatives; OnWeb for iSeries that combines information from multiple applications, databases, and RPG applications, as well as publishes the results directly in HTML or delivers them as a Web service, JavaBean, EJB, or .NET Assembly; and Librados application and technology adapters. Further, the company provides support, maintenance, and technical consultation, as well as applications and management consultancy services. It serves finance, health care, manufacturing, and insurance industries, as well as government agencies in the United States and internationally. The company was founded in 1990 and is headquartered in Cupertino, California.

NETM News:

May 1 - Micro Focus International plc to Acquire NetManage, Inc.

Micro Focus International plc (LSE: MCRO.L) (“Micro Focus”), the leading provider of enterprise application management and modernization solutions, and NetManage, Inc. (NASD: NETM) (“NetManage”), a software company that provides the fastest way to transform legacy applications into new Web-based business solutions, jointly today announced that their respective Boards of Directors have unanimously approved, and both companies have signed, a definitive agreement for Micro Focus to acquire NetManage in a merger transaction.

Pursuant to the terms of the Merger Agreement, Micro Focus will acquire each outstanding share of common stock of NetManage for $7.20 per share, representing a premium of approximately 73% over the closing share price of NetManage's common stock on April 30, 2008 of $4.15. NetManage currently has approximately 9.6 million shares of common stock and 1.6 million options outstanding for an aggregate transaction value of approximately $73.3 million. The acquisition is expected to be completed in June 2008.

Stephen Kelly, Chief Executive Officer of Micro Focus, commented, “The combination of Micro Focus and NetManage will provide the enlarged group with further opportunities for growth through a more comprehensive and broader product offering, enhancing our position as a leading player in the Applications Modernization market.”

Zvi Alon, Chairman and Chief Executive Officer of NetManage, added, “We feel confident this is the right strategy for our shareholders, customers and employees and that Micro Focus will continue to build on our legacy. NetManage's specialized solutions for integrating, Web enabling, and accessing enterprise information systems will strengthen and advance Micro Focus's set of offerings.”

The proposed transaction is subject to the approval of NetManage's stockholders and other customary conditions to closing. All parties desiring details regarding the transaction are urged to review the definitive agreement when it is available on the SEC's website at www.sec.gov. In connection with NetManage's solicitation of proxies with respect to the meeting of shareholders to be called with respect to the proposed transaction, NetManage will file with the SEC, and will furnish to shareholders of NetManage, a proxy statement. NetManage's shareholders are urged to read the proxy statement when it is finalized and distributed to shareholders because it will contain important information. Shareholders will be able to obtain a free-of-charge copy of the proxy statement (when available) and other relevant documents filed with the SEC from the SEC's website at www.sec.gov.

Shareholders will also be able to obtain a free-of-charge copy of the proxy statement and other relevant documents (when available) by directing a request by mail or telephone to NetManage, 20883 Stevens Creek Blvd., Cupertino, California 95014, Attention: Investor Relations, Telephone: (408) 973-7171, or from NetManage's website, www.netmanage.com. NetManage and certain of its directors, executive officers and other members of management and employees may, under the rules of the SEC, be deemed to be “participants” in the solicitation of proxies from shareholders of NetManage in favor of the proposed merger. Information regarding the persons who may be considered “participants” in the solicitation of proxies will be set forth in NetManage's proxy statement when it is filed with the SEC. Information regarding certain of these persons and their beneficial ownership of NetManage common stock as of March 27, 2008 is also set forth in NetManage's Annual Report on Form 10-K for the year ended December 31, 2007.

A number of important factors may affect Micro Focus's and NetManage's actual results and could cause such results to differ materially from forward-looking statements made by or on behalf of Micro Focus and/or NetManage. Such factors include, but are not limited to, changing market conditions, the impact of competitive products and pricing, the timely development, and market acceptance of Micro Focus's and NetManage's products, the timely implementation of certain cost saving measures and other risks detailed herein and from time to time in NetManage's Securities and Exchange Commission filings. NetManage will file the Merger Agreement with the Securities and Exchange Commission on Form 8-K and investors are advised to review the Merger Agreement in its entirety.

ABOUT MICRO FOCUS

Micro Focus, (LSE: MCRO.L), is a London Stock Exchange-listed software company headquartered in the UK which provides innovative software that allows companies to dramatically improve the business value of their enterprise applications. Micro Focus Enterprise Application Modernisation and Management software enables customers' business applications to respond rapidly to market changes and embrace modern architectures with reduced cost and risk. For additional information, visit www.MicroFocus.com.

MESA AIR GROUP INCORPORATED (NASD: MESA)
"Up 45.45% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/MESA.php

Mesa Air Group, Inc., through its subsidiaries, provides scheduled passenger and airfreight services. It carries passengers, as well as freight and express packages on its passenger flights. The company also has interlined small cargo freight agreements with various other carriers. In addition, Mesa Air Group contracts with the U.S. Postal Service for carriage of mail to the cities it serves. Further, it occasionally operates charter flights. As of September 30, 2007, the company operated a fleet of 182 aircraft with approximately 1,100 daily departures to 184 cities in the United States, the District of Columbia, Canada, the Bahamas, and Mexico. Mesa Air Group was founded in 1980 and is headquartered in Phoenix, Arizona.

MESA News:

April 30 - Mesa Air Group Settles Litigation Involving Hawaiian Airlines

Mesa Air Group, Inc. (NASD: MESA) announced that it entered into a settlement with Hawaiian Airlines concerning their long-running lawsuit over Mesa's inter-island flight services operated under the go! brand name. Under the terms of the Settlement and without admitting any wrongdoing, Mesa will receive $37.5 million from the Bond the Company previously posted with the United States Bankruptcy Court for the District of Hawaii. Hawaiian Airlines will be entitled to the remaining collateral of the Bond totaling $52.5 million. This settlement does not restrict in any way go!'s ability to continue to offer services in the Hawaiian interisland market.

Mesa currently operates 182 aircraft with over 1,000 daily system departures to 157 cities, 42 states, the District of Columbia, Canada, the Bahamas and Mexico. Mesa operates as Delta Connection, US Airways Express and United Express under contractual agreements with Delta Air Lines, US Airways and United Airlines, respectively, and independently as Mesa Airlines and go!. In June 2006 Mesa launched inter-island Hawaiian service as go! This operation links Honolulu to the neighbor island airports of Hilo, Kahului, Kona and Lihue. The Company, founded by Larry and Janie Risley in New Mexico in 1982, has approximately 5,000 employees and was awarded Regional Airline of the Year by Air Transport World magazine in 1992 and 2005. Mesa is a member of the Regional Airline Association and Regional Aviation Partners.

H3 ENTERPRISES INCORPORATED (OTC: HTRE)
"Up 48.11% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/HTRE.php

H3 Enterprises Inc. has developed a powerful niche in three of the largest, fastest growing, and most profitable segments in the Entertainment Industry worldwide: Hip Hop Music, Video Gaming, and High Definition Flat Screen TV. These multi-faceted sectors have all been vertically integrated into an award winning franchise that has the opportunity to become the new home of the “Hip Hop Generation”, the most sought after demographic in the world today. In a short period of time, H3 continues to put together the pieces necessary to fully capitalize on the seemingly insatiable appetite for all three of these market monsters through a series of strategic alliances and acquisitions, major celebrity signings, and the construction of a management team second to none.

HTRE News:

May 1 - H3 Set to Announce Major Company Developments

H3 Enterprises, Inc. (OTC: HTRE) President and CEO, Dr. Benjamin Chavis, announced that he has scheduled a national teleconference and live video webcast for Monday, May 5, 2008 at 11:30am EDT. Dr. Chavis will discuss unfolding new developments that will likely have a dynamic impact on the future of H3. To join in the national teleconference dial 1-218-339-7800 and the participant access code is 178920. To view the video webcast, go to www.H3inc.com.

MILLENNIUM CELL INCORPORATED (NASD: MCEL)
"Up 31.91% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/MCEL.php

Millennium Cell, Inc., a development stage company, develops hydrogen batteries for use primarily in portable electronic devices for the military, medical, industrial, and consumer markets. The hydrogen batteries comprise a fuel cell and hydrogen storage technology. The fuel blends used in the hydrogen battery technology include combination of water, sodium borohydride, and other chemicals. The hydrogen produced by its hydrogen fuel cartridge technology is converted into electricity by a fuel cell. The company develops the technology in partnership with corporate and government entities. It also licenses its hydrogen cartridge technology and designs to companies, which develop fuel cell systems. Millennium Cell has a strategic relationship with The Dow Chemical Company for the commercialization of its hydrogen battery technology in the military and consumer electronics markets, as well as has a joint development and licensing agreement with Horizon Fuel Cells Plc. The company was founded in 1998 and is based in Eatontown, New Jersey.

MCEL News:

May 1 - Millennium Cell Updates Stakeholders

Millennium Cell Inc. (NASD: MCEL), a leading developer of hydrogen battery technology, announced that it has not yet raised cash that is necessary to continue its business operations. As previously reported by the Company in its Form 10-K for the year ended December 31, 2007 and during its fourth quarter earnings call, the Company had sufficient cash resources to fund operations into April but not beyond. As a result, the Company has furloughed all employees at this time.

The Board of Directors and senior management are in discussions with third parties that have expressed interest in entering into a potential transaction with the Company, which would provide short term liquidity pending completion and would create value for the Company and its stakeholders for the future. The Company cannot provide any assurances that it will be able to complete any of these potential transactions or, if such a transaction were not completed on reasonable terms, avoid a Bankruptcy proceeding.

Lastly, the Company's request for a hearing to reconsider the de-listing of its common stock on NASDAQ has been granted, and the hearing is scheduled for June 12, 2008. Accordingly, the Company's securities will continue to trade on NASDAQ at least until that time. The Company's ability to present an acceptable plan of compliance to the NASDAQ depends upon its ability to complete one of the potential transactions it is pursuing and NASDAQ's acceptance of its compliance plan.

ZORO MINING CORPORATION (OTCBB: ZORO)
"Up 43.08% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/ZORO.php

Zoro Mining Corp. engages in the acquisition, exploration, and development of mineral properties in North America, South America, and Mexico. It has an option to acquire a 100% interest in six mineral property covering approximately 39,787 gross acres located in Chile, Peru, and Mexico with a focus on gold and copper prospects. The company was founded in 2004 under the name Rochdale Mining Corp. and changed its name to Zoro Mining Corp. in March 2007. Zoro Mining Corp. is based in Tucson, Arizona.

ZORO News:

May 1 - Zoro Mining Has Contracted for 8,000 Meters of Diamond Drilling at Its Don Beno Project, Region III Chile

Zoro Mining Corp. (OTCBB: ZORO) announced that it is ready to commence up to an 8,000 meter (26,000 feet) diamond drilling program at its 100% owned Don Beno gold-copper project located 100 km from Copiapo in Region III, Chile. This drill program has been designed to drill targets from a recently completed geophysical I.P. survey.

The geophysical mapping program at Don Beno, conducted by HydroGeophysics of Tucson, Arizona, included both electrical resistivity and induced polarization (IP) methods along linear transects of up to 8 km in length. Several large sulfidic IP targets were identified through approximately 33 line-kilometers among 5 transects.

The targets are open ended to depth. The largest of the IP anomalies identified is roughly 4km by 2km in size, where the depth from surface to the sulfide mineralization is expected to be as little as 60 meters.

To view a map, click http://media3.marketwire.com/docs/zoro_map.jpg.

These anomalies appear to be part of a system associated with targets which are presently defined or being drilled, on concessions directly adjoining Don Beno, currently being pursued by both SAMEX Mining Corp. and IPBX Resources.

The Don Beno diamond drilling program will focus on the largest identified IP anomaly. Zoro has contracted for diamond drilling with PerfoAndes, a Chilean drilling company, which anticipates rig site mobilization and startup at the beginning of May, 2008. The holes will vary in depth but are envisioned to average approximately 500 meters.

Zoro's main holdings are in the Don Beno, Escondida, Costa Rica and Rio Sur Districts in Chile, and the Yura District in Peru.

You can find more detailed information with respect to the company's projects, corporate information and leadership team by visiting the company's website at www.zoromining.com.

HEALTH DISCOVERY CORPORATION (OTCBB: HDVY)
"Up 32.00% on Thursday"

Detailed Quote: http://www.otcpicks.com/quotes/HDVY.php

Health Discovery Corporation operates as a pattern recognition company that uses mathematical techniques to analyze large amounts of data to uncover patterns. It licenses its support vector machines and fractal genomic modeling technologies to diagnostic and pharmaceutical companies. The company's discoveries include a subset of genes that separates BPH from prostate cancer and BPH from normal tissue patterns; a genetic biomarker signature, which identifies clinically high grade prostate cancer based on analysis of tissue samples; a set of leukemia genes that separates ALL-T-cell leukemia from ALL-B-cell leukemia; colon cancer-specific biomarkers, which is used in the development of diagnostic assays for cancer detection, disease discrimination, and potential vaccine; and an AIDS expression signature that separates AIDS brain cells from non-AIDS brain cells. It is also developing two breast cancer diagnostic technologies, including MammoSIGHT for detecting malignancy in mammograms; and MetastaSIGHT for identifying circulating tumor cells in the blood. The company was founded in 2001. It was formerly known as Direct Wireless Communications, Inc. and changed its name to Health Discovery Corporation in 2003. Health Discovery is based in Savannah, Georgia.

HDVY News:

April 30 - Health Discovery Corporation Announces Successful Clinical Trial Results for New Molecular Diagnostic Test for Prostate Cancer

New Prostate Cancer Test Demonstrates Very High Accuracy Rate for Detecting Prostate Cancer

Health Discovery Corporation (OTCBB: HDVY) (“HDC”) announced the successful clinical trial results for HDC’s new molecular diagnostic test for prostate cancer licensed exclusively to Clarient (NASD: CLRT), in which HDC will receive a 30 percent royalty based on reimbursements received by Clarient from third parties.

The initial clinical validation study recently completed at Clarient from prostate tissues obtained in collaboration with MD Anderson Cancer Center demonstrated a very high success rate for identifying the presence of Grade 3 or higher prostate cancer cells (clinically significant cancer) in prostate cancer tissue. The new molecular diagnostic test achieved a Sensitivity of 100% meaning that the test correctly identified genomic evidence of prostate cancer cells in every tissue specimen known to be positive for prostate cancer. The test also demonstrated a very high success rate for correctly identifying those prostate specimens that did not have prostate cancer as being negative for prostate cancer and achieved a Specificity of 80% for identifying the non-cancer tissues, which included normal and benign prostatic hypertrophy (BPH) tissue, as not having genomic evidence of cancer.

In the United States alone there are over 1 million prostate cancer tissue biopsy procedures performed annually. Approximately 25% of these tissue biopsies are reported “positive” indicating the presence of prostate cancer. The other 75% of prostate cancer tissue biopsies are reported as “negative” for the presence of cancer. However, one-third of the men with prostate cancer tissue biopsies that are reported as “negative” for prostate cancer (roughly 25%) actually do have prostate cancer that was missed by the first biopsy (False Negative). These men actually have prostate cancer that was missed by the initial tissue biopsy for a variety of reasons. Health Discovery Corporation’s prostate cancer molecular diagnostic test is a genomics based test discovered using HDC’s patented SVM and SVM-RFE pattern recognition technology. This prostate cancer test is based on a unique combination of 4 genes that accurately identify the presence of Grade 3 or higher (clinically significant cancer) prostate cancer cells in prostate tissue.

HDC and Clarient will now move to phase two of the clinical trial process to increase the number of specimens tested in order to achieve the statistical significance necessary to validate these very successful initial results. Once the next phase of clinical testing is completed, The Companies will begin the commercialization process. Assuming the data continues to support these initial findings, it is possible that the product could be made available for clinical use by late Q3 of 2008 under the current CLIA regulations.

“We are thrilled with the results of this clinical trial and look forward to the commercial launch of this new prostate cancer test with Clarient,” stated Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “The success of this clinical trial also demonstrates that HDC, using our patented SVM and SVM-RFE technology, can develop new molecular diagnostic tests from conception of the idea through clinical discovery and validation of unique genomic signatures that can be commercialized as new molecular diagnostic tests. Our patent protected discovery method allows to us to develop molecular diagnostic tests that are free of outside intellectual property rights and thereby allows HDC to fully patent protect our discovery. We are currently duplicating this process to develop new molecular diagnostic tests in a variety of other cancers.”

Dr. Barnhill continued “We are looking forward to having HDC’s new prostate cancer test commercialized like similar molecular diagnostic tests based on unique gene expression profiles such as OncotypeDX from Genomic Health, Inc. (NASD: GHDX) and MammaPrint from Agendia.”

“The results of this clinical trial demonstrating genomic evidence of the presence of prostate cancer in prostate cancer tissue with 100% accuracy is a remarkable accomplishment,” stated Dr. Herbert Fritsche, Professor of Laboratory Medicine and Chief of the Clinical Chemistry Section at The University of Texas, M.D. Anderson Cancer Center in Houston, Texas. “Health Discovery Corporation’s ability to develop state-of-the-art molecular diagnostic tests for cancer combined with Clarient’s ability to successfully commercialize these tests can provide a significant benefit to cancer patients and their physicians.”

Savannah-based Health Discovery Corporation (OTCBB: HDVY) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a biology-oriented biomarker discovery company providing all aspects of First-Phase Biomarker Discovery(sm). The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as radiology, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.